RBC Capital Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $445

RBC Capital analyst Luca Issi maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $450 to $445.